An interesting case from a PRMT5 inhibitor trial (PRT811) noted a complete response in a patient with an IDH1-mutant GBM (Xiao et al., 2019) – IDH-mutant tumors often have low EZH2 due to their hypermethylated state, raising the idea that maybe combining EZH2 inhibition with other targeted agents is more useful in IDH-wildtype context. The gene discussed is IDH1; the disease is glioblastoma.